Sanofi starts PhIII C-diff study; Sanford-Burnham vice chair dies following accident; BIO launches new job site;

@FierceBiotech: Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. News | Release | Follow @FierceBiotech

@JohnCFierce: India revokes divisional patents on Herceptin. These emerging markets sure can be quite nettlesome. Report | Follow @JohnCFierce

@RyanMFierce: Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More from FierceBiotechIT | Follow @RyanMFierce

> Sanofi ($SNY) has started a Phase III trial for a new vaccine for Clostridium difficile infection, which requires up to $7 billion a year in acute care costs in the U.S. and Europe. Release

> Duane Roth, vice chairman of Sanford-Burnham's Board of Trustees, died over the weekend following a bicycle accident in July. Story

> The Biotechnology Industry Organization has launched a new site for industry jobs. Report

> The Spanish National Cancer Research Center is laying off 64 staffers--including 28 scientists--following some severe budgeting problems. Story

> By the end of 2013, Ultragenyx Pharmaceuticals plans to kick off a Phase II trial for its candidate triheptanoin (UX007) for combating seizures in patients with a rare disease called glucose transporter type-1 deficiency syndrome (Glut1 DS). Release

Pharma News

@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter exemplify very real challenges. Article | Follow @EricPFierce

@CarlyHFierce: Roche signs agreement to make drug that prevents blindness in HIV patients available in developing nations. Release | Follow @CarlyHFierce

> J&J slapped with HHS subpoena on Nucynta marketing. Story

> India hits Roche's Herceptin in latest blow to Big Pharma patents. More

> Drug shortage complicates execution schedule for death penalty leader Texas. Article

Medical Device News

@FierceMedDev: ICYMI Friday: Abiomed swings to loss on legal costs. Story | Follow @FierceMedDev

@MarkHFierce: ConforMIS, armed with $167.7M expanded series E, plots global marketing expansion. Report | Follow @MarkHFierce

@DamianFierce: Gore prevailed over St. Jude in a patent lawsuit over heart plugs. News | Follow @DamianFierce

@MichaelGFierce: Halozyme regrouping after ViroPharma trial flop. More from FierceDrugDelivery | Follow @MichaelGFierce

> M&A report: Theragenics agrees to $68M buyout. Story

> Stryker CEO: So far, so good after one year. Item

CRO News

> Charles River boosts sales as charges drag profits. Article

> INC expands in Japan as local market soars. Story

> Clinipace reaches into the north with CRO partnership. Item

> Quintiles posts flat revenue as charges swallow profits. Report

> Covance swings to profit despite tough early-phase market. More

> KKR buying RPS, planning to merge it with PRA. Article

Biotech IT News

> China pharma R&D drives expanded use of Medidata software. News

> Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More

> Accelrys to ax 80 jobs after drop in quarterly profits. News

> Battle against breast cancer goes open source. Story

> Ex-Yahoo CEO backs genomics big data startup Bina. Article

And Finally… Scientists at Vanderbilt say that inhibiting the COX-2 enzyme could relieve anxiety by activating natural "endocannabinoids" without gastrointestinal side effects. Release